Data fra et åbent studie (PROTECT), som undersøgte sikkerheden ved administration af PDT med verteporfin og Lucentis 0, 5 mg samme dag hos 32 patienter fulgt i 9 måneder, viste at antallet af tilfælde med intraokulære inflammationer i forbindelse med en initial behandling var 6, 3% (2 ud af 32 patienter).
Data from an open label study (PROTECT) in 32 patients followed for 9 months in which the safety of same-day administration of verteporfin PDT and Lucentis 0.5 mg was evaluated showed that the incidence of intraocular inflammation following the initial treatment was 6.3% (2 of 32 patients).